Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Jun 10 2010

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/SNSS

Sunesis Pharmaceuticals Inc. (SNSS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for oncology. The Company's experienced cancer drug development organization is committed to advancing voreloxin through clinical trials. The Company's lead compound, voreloxin, is currently being evaluated as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer, in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeloid leukemia (AML) patients unlikely to benefit from standard induction chemotherapy and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types. SNSS has also formed strategic research and drug discovery partnerships with leading pharmaceutical and biopharmaceutical companies, including Biogen Idec Inc. and SARcode Corp.

Message Board Search for SNSS: http://www.boardcentral.com/boards/SNSS

In the report, the analyst notes:

"The Company recently announced the updated clinical data from Phase 2 clinical studies of its lead drug candidate, voreloxin, in acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. According to the report, 'Clinical data from the SNSS's Phase 2 clinical trial of voreloxin in combination with cytarabine in first relapsed or primary refractory AML exhibit a meaningful improvement in overall survival relative to literature-based values reported for current treatment standards of care, including cytarabine-based regimens.'

"The recent clinical findings, along with formal feedback from both U.S. and EU regulatory agencies, support the Company's plan to initiate a Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed AML patient population in the second half of 2010."